

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-409US1	Application No. 10/561,014
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Shuchong Pan et al.	
		Filing Date December 16, 2005	Group Art Unit 1649

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	4,034,074	07/05/77	Miles			
	2	4,098,876	07/04/78	Piasio et al.			
	3	4,233,402	11/11/80	Maggio et al.			
	4	4,996,143	02/26/91	Heller et al.			
	5	5,114,923	05/19/92	Seilhamer et al.			
	6	5,296,347	03/22/94	LaMotte, III			
	7	5,565,322	10/15/96	Heller			
	8	5,580,859	12/03/96	Felgner et al.			
	9	5,583,108	12/10/96	Wei et al.			
	10	5,589,466	12/31/96	Felgner et al.			
	11	5,849,489	12/15/98	Heller			
	12	6,124,430	09/26/00	Mischak et al.			
	13	6,162,603	12/19/00	Heller			
	14	6,376,207	04/23/02	Mischak et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	15	WO 84/03825	10/11/84	WIPO				
	16	WO 00/71576	11/30/00	WIPO				
	17	WO 01/44284	06/21/01	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	18	Abdelhafiz, "Heart failure in older people: causes, diagnosis and treatment," <u>Age Ageing</u> , 2002, 31(1):29-36
	19	Best et al., "Dendroaspis natriuretic peptide relaxes isolated human arteries and veins," <u>Cardiovas. Res.</u> , 2002, 55:375-384
	20	Burger and Burger, "BNP in decompensated heart failure: Diagnostic, prognostic and therapeutic potential," <u>Curr. Opin. Investig. Drugs</u> , 2001, 2(7):929-35

Examiner Signature /Chang-Yu Wang/	Date Considered 11/30/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.Y.W

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-409US1	Application No. 10/561,014
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Shuchong Pan et al.	
		Filing Date December 16, 2005	Group Art Unit 1649

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	21	Chaurand et al., "Peptide and Protein Identification by Matrix-Assisted Laser Desorption Ionization (MALDI) and MALDI-Post-Source Decay Time-of-Flight Mass Spectrometry," <u>J. Am. Soc. Mass Spectrom.</u> , 1999, 10(2):91-103
	22	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," <u>Monoclonal Antibodies and Cancer Therapy</u> , 1985, Alan R. Liss, Inc., pp. 77-96
	23	Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens," <u>Proc. Natl. Acad. Sci. USA</u> , 1983, 80:2026-2030
	24	Cowie and Mendez, "BNP and Congestive Heart Failure," <u>Prog. Cardiovasc. Dis.</u> , 2002, 44(4):293-321
	25	Gevaert et al., "Protein identification based on matrix assisted laser desorption/ionization-post source decay-mass spectrometry," <u>Electrophoresis</u> , 2001, 22(9):1645-51
	26	Guatelli et al., "Isothermal, <i>in vitro</i> amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication," <u>Proc. Natl. Acad. Sci. USA</u> , 1990, 87:1874-1878
	27	Huse et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 1989, 246:1275-1281
	28	Hyrup and Nielsen, "Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications," <u>Bioorgan. Med. Chem.</u> , 1996, 4:5-23
	29	Köhler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> , 1975, 256:495-497
	30	Kozbor and Roder, "The production of monoclonal antibodies from human lymphocytes," <u>Immunology Today</u> , 1983, 4:72-79
	31	Lewis, "PCR's Competitors Are Alive and Well and Moving Rapidly Towards Commercialization," <u>Genetic Engineering News</u> , 1992, 12(9):1-3
	32	Peacock, "The B-type natriuretic peptide assay: a rapid test for heart failure," <u>Cleve. Clin. J. Med.</u> , 2002, 69(3):243-251
	33	Richards et al., "BNP in hormone-guided treatment of heart failure," <u>Trends Endocrinol. Metab.</u> , 2002, (5):151-155
	34	Sagnella, "Practical implications of current natriuretic peptide research," <u>J. Renin. Angiotensin Aldosterone Syst.</u> , 2000, 1(4):304-315
	35	Ausubel et al. (eds.), <u>Short Protocols in Molecular Biology</u> , 1992, Chapters 8 and 11, Green Publishing Associates and John Wiley & Sons
	36	Summerton and Weller, "Morpholino Antisense Oligomers: Design, Preparation, and Properties," <u>Antisense Nucleic Acid Drug Dev.</u> , 1997, 7:187-195
	37	Tremblay et al., "Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases," <u>Mol. Cell. Biochem.</u> , 2002, 230(1-2):31-47
	38	Walther et al., "Natriuretic peptide system in fetal heart and circulation," <u>J. Hypertens.</u> , 2002, 20(5):786-791
	39	Weiss, "Hot Prospect for New Gene Amplifier," <u>Science</u> , 1991, 254:1292-1293

Examiner Signature /Chang-Yu Wang/	Date Considered 11/30/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	